The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...

Neurizon Therapeutics has reported positive topline results from an open-label extension (OLE) study of its lead candidate ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Researchers genetically reprogrammed mouse nerve cells to reverse cell aging, delaying the onset of ALS symptoms in the animals.

Raffaella Uccelli, Alessandra Binazzi, Pierluigi Altavista, Stefano Belli, Pietro Comba, Marina Mastrantonio, Nicola Vanacore, Geographic distribution of amyotrophic lateral sclerosis through motor ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease predominantly affecting upper and lower motor neurons. Here, the authors outline previous and current efforts to characterize ...